Made available in DSpace on 2016-01-07T13:36:23Z (GMT). No. of bitstreams: 2
andressa_martorelli_ioc_mest_2014.pdf: 1406086 bytes, checksum: aa1b67f7a16391a611cf88b0ce6ca128 (MD5)
license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5)
Previous issue date: 2015-11-23 / Indivíduos infectados pelo HIV têm um risco mais elevado de serem afetados por doenças graves, tais como infecções por vírus respiratórios, incluindo o vírus da influenza. A imunossupressão desses indivíduos pode afetar a sua capacidade de resposta à imunização ativa. A vacinação contra o vírus influenza ainda representa a principal forma de reduzir o impacto deste vírus. Devido à circulação em 2009 do vírus influenza pandêmico A (H1N1) pdm09 e influenza sazonal A (H3N2) e vírus B, a composição atual vacina incluem antígenos destes três agentes em sua formulação. Assim, a análise do impacto da vacina trivalente inativada contra influenza (TIV) em indivíduos infectados pelo HIV merece mais estudos. Uma coorte de 131 indivíduos HIV- 1 positivos, com viremia controlada recebeu duas doses únicas de TIV com 21 dias de intervalo. Os títulos de anti- hemaglutinantes (HA) de seus soros foi avaliada em diferentes pontos de tempo (dias zero, 21 e 42, bem como seis meses pós- vacinação). No que diz respeito à resposta imune ao vírus A(H1N1) pdm09 , observouse que um ano depois de ter recebido a vacina monovalente contra este antígeno , 62,6% dos indivíduos permaneceram soroprotegidos, uma queda de 20% em relação à 6 meses pósvacinação monovalente no ano de 2010. Além disso, após a primeira dose de TIV, títulos soroprotetores foram encontrados em todos os indivíduos
A soroproteção de baseline para os antígenos H3N2 e influenza B foi de 67,9% e 27,5%, respectivamente. Em relação à soroconversão, observamos que 19,8% e 21% dos indivíduos apresentavam títulos antihemaglutinantes para o vírus A(H1N1)pdm09, 21 e 42 dias pós-vacinação com TIV, respectivamente. A soroconversão para o antígeno H3N2 foi 15,7% e 16% aos 21 e 42 dias respectivamente. Em relação à Influenza B, 35,7% e 38,6% dos indivíduos soroconverteram aos 21 e 42 dias após a vacinação. Aos seis meses pós-vacinação, os títulos de anti \2013 hemaglutinantes dos soros caiu para abaixo 15,7% para o antígeno A(H1N1)pdm09, 14,4% para H3N2 e 29,1% para antígenos de influenza B. Observamos também que indvíduos com maiores contagem de células CD4 resposram melhor a vacinação frente ao virus influenza B. Em conjunto, nossos resultados indicam que indíviduos HIV-1 positivos apresentam melhores repostas humorais para os antígenos A(H1N1)pdm09, quando comparado com os outros dois antígenos presentes na TIV / HIV
-
infected
individuals have a higher risk of being affected by serious illnesses , such as
in
fections by respiratory viruses
, including influenza virus . Immunosuppression
of
these
individuals can affect their ability to
respond to active immunization
. Vaccination against
influenza is still the main way to
reduce the impact of this virus
. Due to the movement
in
2009 pandemic influenza A (H1N1)
pdm09
and seasonal influenza
A (H3N2) and B viruses
,
the current vaccine composition include antigens of these
three agents in their formula
tion
.
Thus, analysis of the impact of trivalent
inactivated influenza vaccine (TIV
) in HIV
-
infected
individuals deserves further study. A cohort of 131 HIV
-
1 positive individuals with controlled
viremia received two single dose
s of TIV 21 days apart. Th
e titers of anti
-
hemagglutinant
(HA
) of their sera was assessed
at different time points (zero, 21,
42 days a
nd six months
post
-
vaccination)
. With re
gard to immune to the virus A (H1N1)
pdm09 response , it was
noted that a year af
ter having received the monovalent vaccine against this antigen , 62.6 % of
subjects remained seroprotection , a decrease of 20 % compared to 6 monovalent months
post
-
vaccination in 2010 . Moreover, after the first dose of TIV
, seroprotective titers were
f
ound in all
individuals
. The seroprotection baseline for H3N2 and influenza B
antigens was
67.9 % and 27.5 %
, respectively
. Regarding to seroconversion
, we found that 19.8 %
and 21
% of subjects had anti
-
hemag
glutinin titles for the A (H1N1)pdm09
, 21 and
42
days post
-
vaccination with TIV
, respectively. Seroconversion for H3N2 antigen was 15.7% and 16 % at
21 and 42 days resp
ectively. Regarding Influenza B
, 35.7 % and 38.6 % of subjects
seroconverted after 21 and 42 days after vaccination. At six months po
st
-
vac
cination , the
titers of anti
-
hemagglutinin sera fe
ll below 15.7 % for antigen A (H1N1)pdm09
, 14.4% to
29.1 % for H3N2 and influenza B antigens
.
We also observed that indvíduos with higher CD4
cell counts resposram best vaccination against the influ
enza virus B. Together, our results
indicate that HIV
-
1 positive individuals show better humoral responses to antigens A (H1N1)
pdm09 compared with others two antigens present in the TIV. / HIV
-
infected
individuals have a higher risk of being affected by serious illnesses , such as
in
fections by respiratory viruses
, including influenza virus . Immunosuppression
of
these
individuals can affect their ability to
respond to active immunization
. Vaccination against
influenza is still the main way to
reduce the impact of this virus
. Due to the movement
in
2009 pandemic influenza A (H1N1)
pdm09
and seasonal influenza
A (H3N2) and B viruses
,
the current vaccine composition include antigens of these
three agents in their formula
tion
.
Thus, analysis of the impact of trivalent
inactivated influenza vaccine (TIV
) in HIV
-
infected
individuals deserves further study. A cohort of 131 HIV
-
1 positive individuals with controlled
viremia received two single dose
s of TIV 21 days apart. Th
e titers of anti
-
hemagglutinant
(HA
) of their sera was assessed
at different time points (zero, 21,
42 days a
nd six months
post
-
vaccination)
. With re
gard to immune to the virus A (H1N1)
pdm09 response , it was
noted that a year af
ter having received the monovalent vaccine against this antigen , 62.6 % of
subjects remained seroprotection , a decrease of 20 % compared to 6 monovalent months
post
-
vaccination in 2010 . Moreover, after the first dose of TIV
, seroprotective titers were
f
ound in all
individuals
. The seroprotection baseline for H3N2 and influenza B
antigens was
67.9 % and 27.5 %
, respectively
. Regarding to seroconversion
, we found that 19.8 %
and 21
% of subjects had anti
-
hemag
glutinin titles for the A (H1N1)pdm09
, 21 and
42
days post
-
vaccination with TIV
, respectively. Seroconversion for H3N2 antigen was 15.7% and 16 % at
21 and 42 days resp
ectively. Regarding Influenza B
, 35.7 % and 38.6 % of subjects
seroconverted after 21 and 42 days after vaccination. At six months po
st
-
vac
cination , the
titers of anti
-
hemagglutinin sera fe
ll below 15.7 % for antigen A (H1N1)pdm09
, 14.4% to
29.1 % for H3N2 and influenza B antigens
.
We also observed that indvíduos with higher CD4
cell counts resposram best vaccination against the influ
enza virus B. Together, our results
indicate that HIV
-
1 positive individuals show better humoral responses to antigens A (H1N1)
pdm09 compared with others two antigens present in the TIV
| Identifer | oai:union.ndltd.org:IBICT/oai:www.arca.fiocruz.br:icict/12498 |
| Date | January 2014 |
| Creators | Marttorelli, Andressa |
| Contributors | Cruz, Daniella Arêas Mendes da, Morgado, Mariza, Couceiro, José Nelson dos Santos Silva, Volotão, Eduardo de Mello, Caetano, Braulia Costa, Souza, Thiago Moreno Lopes e |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Source | reponame:Repositório Institucional da FIOCRUZ, instname:Fundação Oswaldo Cruz, instacron:FIOCRUZ |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0029 seconds